{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:17:02Z","timestamp":1792196222887,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2411,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1093\/annonc\/mdt008","type":"journal-article","created":{"date-parts":[[2013,2,9]],"date-time":"2013-02-09T03:42:22Z","timestamp":1360381342000},"page":"1513-1525","source":"Crossref","is-referenced-by-count":62,"title":["Genetic variability in the multidrug resistance associated protein-1 (ABCC1\/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)"],"prefix":"10.1016","volume":"24","author":[{"given":"C.","family":"Vulsteke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dieudonn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hatse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Brussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Belmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Paridaens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt008_bb0010","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients. The FNCLCC PACS 01 Trial","volume":"24","author":"Roch\u00e9","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt008_bb0015","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2010.28.8043","article-title":"Physical and psychosocial recovery in the year after primary treatment of breast cancer","volume":"9","author":"Ganz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt008_bb0020","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jnci\/djj305","article-title":"Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer","volume":"98","author":"Hasset","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt008_bb0025","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0959-8049(02)00151-X","article-title":"Dose strategies for anticancer drugs: the good, the bad and body-surface area","volume":"38","author":"Felici","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt008_bb0030","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.ejca.2003.12.026","article-title":"Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy","volume":"40","author":"Rudek","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt008_bb0035","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2165\/00003495-199856060-00006","article-title":"Practical treatment guide for dose individualisation in cancer chemotherapy","volume":"56","author":"Canal","year":"1998","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdt008_bb0040","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0936-6555(05)80297-3","article-title":"Population and Bayesian pharmacokinetics in oncology","volume":"6","author":"Ranson","year":"1994","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1093\/annonc\/mdt008_bb0045","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.1996.14.11.3000","article-title":"Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541","volume":"14","author":"Rosner","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt008_bb0050","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American society of clinical oncology clinical practice guideline","volume":"30","author":"Griggs","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt008_bb0055","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1067\/mcp.2002.128867","article-title":"Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer","volume":"72","author":"Di Paolo","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1093\/annonc\/mdt008_bb0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/bjc.1989.226","article-title":"A limited sampling procedure for estimating Adriamycin pharmacokinetics in cancer patients","volume":"60","author":"Launay","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt008_bb0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF00685852","article-title":"A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans","volume":"36","author":"Marchiset-Leca","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdt008_bb0070","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt008_bb0075","first-page":"1117","article-title":"Polymorphism C3435T of the MDR-1 predicts response to preoperative chemotherapy in locally advanced breast cancer","volume":"22","author":"Kafka","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1093\/annonc\/mdt008_bb0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/CBI20110264","article-title":"ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia","volume":"36","author":"Semsei","year":"2012","journal-title":"Cell Biol Int"},{"key":"10.1093\/annonc\/mdt008_bb0085","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic Prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J Clin Onc"},{"key":"10.1093\/annonc\/mdt008_bb0090","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"10.1093\/annonc\/mdt008_bb0095","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"Van Kuilenburg","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt008_bb0100","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"Van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt008_bb0105","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G >A mutation causing DPD deficiency","volume":"7","author":"Van Kuilenbrug","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt008_bb0110","first-page":"477","article-title":"Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"2","author":"Takimoto","year":"1996","journal-title":"Clin Cancer res"},{"key":"10.1093\/annonc\/mdt008_bb0115","first-page":"2832","article-title":"Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2019-splice donor site of intron 14 in patients with severe 5-fluorouracil (5FU)-related toxicity compared with controls","volume":"7","author":"Raida","year":"2001","journal-title":"Clin Cancer res"},{"key":"10.1093\/annonc\/mdt008_bb0120","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol Cancer ther"},{"key":"10.1093\/annonc\/mdt008_bb0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jnci\/djh015","article-title":"Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate","volume":"96","author":"Sohn","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt008_bb0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2009.03556.x","article-title":"Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients","volume":"69","author":"Etienne-Grimaldi","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdt008_bb0135","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/FPC.0b013e328045c4fb","article-title":"Genetic polymorphisms of CYP2B6 affect the pharmacokinetics\/pharmacodynamics of cyclophosphamide in japanese cancer patients","volume":"17","author":"Nakajima","year":"2007","journal-title":"Pharmacogenet Genom"},{"key":"10.1093\/annonc\/mdt008_bb0140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/leu.2008.323","article-title":"Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia","volume":"23","author":"Rocha","year":"2008","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdt008_bb0145","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","article-title":"Influence of pharmacogentics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide","volume":"102","author":"Bray","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt008_bb0150","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/bcr2570","article-title":"Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study","volume":"12","author":"Gor","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdt008_bb0155","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2006.10.0099","article-title":"Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer","volume":"25","author":"Udler","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt008_bb0160","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ijc.10896","article-title":"Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment","volume":"103","author":"Sweeney","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdt008_bb0165","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.2006.02690.x","article-title":"Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus","volume":"62","author":"Zhong","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdt008_bb0170","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2005.04.8587","article-title":"FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer","volume":"24","author":"Thussbas","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt008_bb0175","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.155","article-title":"NAD(P)H: quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer","volume":"40","author":"Fagerholm","year":"2008","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdt008_bb0180","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10549-007-9764-8","article-title":"Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer","volume":"111","author":"Bewick","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt008_bb0185","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3816\/CCC.2001.n.018","article-title":"Thymidylate synthase pharmacogenetics in colorectal cancer","volume":"1","author":"Marsh","year":"2001","journal-title":"Clin Colorectal Cancer"},{"key":"10.1093\/annonc\/mdt008_bb0190","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/annonc\/mdq212","article-title":"Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients","volume":"21","author":"Sun","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt008_bb0195","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/FPC.0b013e32801233fc","article-title":"Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide\/methotrexate\/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer","volume":"17","author":"Jaremko","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1093\/annonc\/mdt008_bb0200","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1349-7006.2009.01186.x","article-title":"Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma","volume":"100","author":"Lai","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1093\/annonc\/mdt008_bb0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2009.45","article-title":"Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients","volume":"10","author":"Khrunin","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"10.1093\/annonc\/mdt008_bb0210","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nmeth.1974","article-title":"The 1000 Genomes Project: data management and community access","volume":"9","author":"Clarke","year":"2012","journal-title":"Nat Methods"},{"key":"10.1093\/annonc\/mdt008_bb0215","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nbt.2053","article-title":"Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing","volume":"30","author":"Reumers","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1093\/annonc\/mdt008_bb0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/gepi.20164","article-title":"Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studies","volume":"30","author":"Sun","year":"2006","journal-title":"Genet Epidemiol"},{"key":"10.1093\/annonc\/mdt008_bb0225","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gr.GR-1649R","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"11","author":"Dean","year":"2001","journal-title":"Genome Res"},{"key":"10.1093\/annonc\/mdt008_bb0230","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1360704","article-title":"Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line","volume":"258","author":"Cole","year":"1992","journal-title":"Science"},{"key":"10.1093\/annonc\/mdt008_bb0235","first-page":"1237","article-title":"Tissue distribution of the multidrug resistance protein","volume":"148","author":"Flens","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdt008_bb0240","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2174\/092986708785132870","article-title":"Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development","volume":"15","author":"Zhou","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1093\/annonc\/mdt008_bb0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1742-7843.2010.00642.x","article-title":"In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA","volume":"108","author":"Wu","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1093\/annonc\/mdt008_bb0250","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/FPC.0b013e328350e270","article-title":"The G671V variant of MRP1\/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal","volume":"22","author":"Jungsuwadee","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1093\/annonc\/mdt008_bb0255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt008_bb0260","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","article-title":"Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma","volume":"77","author":"Wildiers","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdt008_bb0265","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clpt.2003.10.006","article-title":"A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity","volume":"75","author":"Duguay","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1093\/annonc\/mdt008_bb0270","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/leu.2008.398","article-title":"Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21","volume":"23","author":"Rossi","year":"2009","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdt008_bb0275","article-title":"A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracl\/leucovorin\/oxaliplatin (FOLFOX4) regimen","author":"Cecchin","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"10.1093\/annonc\/mdt008_bb0280","first-page":"201","article-title":"Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with acute myeloid leukemia","volume":"1","author":"Hampras","year":"2010","journal-title":"Int J Mol Epidemiol Genet"},{"key":"10.1093\/annonc\/mdt008_bb0285","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/FPC.0b013e328313aaa4","article-title":"Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin","volume":"18","author":"Ekhart","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1093\/annonc\/mdt008_bb0290","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/14622416.9.3.277","article-title":"Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids","volume":"9","author":"Kirchheiner","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1093\/annonc\/mdt008_bb0295","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-200645030-00003","article-title":"Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer","volume":"45","author":"Bosch","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/annonc\/mdt008_bb0300","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/sj.tpj.6500330","article-title":"Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19","volume":"5","author":"Timm","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"10.1093\/annonc\/mdt008_bb0305","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/art.20338","article-title":"Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis","volume":"50","author":"Takada","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdt008_bb0310","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"Van Schaik","year":"2002","journal-title":"Clin Chem"},{"key":"10.1093\/annonc\/mdt008_bb0315","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2217\/pgs.12.69","article-title":"UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients","volume":"13","author":"Tian","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"15s","key":"10.1093\/annonc\/mdt008_bb0320","article-title":"Germline Single Nucleotide Polymorphims (SNPS) in XRCC3, XRCC1 and XPD and survival outcomes after adjuvant chemotherapy in early breast cancer patients","volume":"28","author":"Marcos","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419372965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419372965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/6\/1513\/13788949\/mdt008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:05:17Z","timestamp":1624698317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419372965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0923753419372965"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt008","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}